{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.61","value":"10.69"}]}],"title":"WBC count pre-LD chemo"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.43","value":"6.09"}]}],"title":"WBC count day 30"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.22","value":"7.61"}]}],"title":"WBC count day 90"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.75","value":"6.11"}]}],"title":"WBC count day 180"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.61","value":"6.96"}]}],"title":"WBC count day 365"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"The cellular composition of marrow (WBC Count) will be quantified at the specified timepoints by flow cytometry.","dispersionType":"Standard Deviation","groups":[{"description":"Patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m\\^2 and fludarabine 30mg/m\\^2 for 3 consecutive days followed by the infusion of BCMA CAR T-cells at a target dose of 450 x10\\^6 cells. Maintenance lenalidomide, starting at 5mg a day for 21 days of a 28-day cycle will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the patient reaches 12 months post CAR T-cell infusion and continue free of progression.\n\nLenalidomide: Maintenance lenalidomide, starting at 5 mg a day for 21 days of a 28-day cycle, will be initiated at a minimum of at least 30 days, but no later than 180 days after the CAR T-cell infusion and will continue until the participant reaches 12 months post CAR T-cell infusion and continues free of progression\n\nbb2121: Participants receive infusion of BCMA CAR T-cells at a target dose of 450 x 10\\^6 cells.\n\nCyclophosphamide: 300 mg/m\\^2/day for 3 consecutive days prior to the CAR T infusion\n\nFludarabine: 30 mg/m\\^2/day or 3 consecutive days prior to the CAR T infusion\n\nleukapheresis: Placement of central line catheter and leukapheresis","id":"OG000","title":"Lenalidomide and bb2121"}],"paramType":"MEDIAN","populationDescription":"Participants who received an infusion","reportingStatus":"POSTED","timeFrame":"Pre-LD chemo, Day 30, 90, 180, 365","title":"Exploratory Objective 2: Immune Reconstitution (WBC)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"x10^3 cells/uL"}